

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

Vyera Pharmaceuticals, LLC, *et al.*,¹

Debtors.

Chapter 11, Subchapter V

Case No. 23-10605 (JKS)

(Jointly Administered)

**GLOBAL NOTES AND STATEMENTS OF LIMITATIONS, METHODOLOGY,
AND DISCLAIMERS REGARDING DEBTORS' SCHEDULES OF ASSETS
AND LIABILITIES AND STATEMENTS OF FINANCIAL AFFAIRS**

Introduction

The Schedules of Assets and Liabilities (collectively, the “Schedules”) and Statements of Financial Affairs (collectively, the “Statements,” and, together with the Schedules, the “Schedules and Statements”) filed by Vyera Pharmaceuticals, LLC (“Vyera”), Oakrum Pharma, LLC, SevenScore Pharmaceuticals, LLC, Dermelix Biotherapeutics, LLC, Phoenixus AG, and Orpha Labs AG (collectively, the “Debtors”), as debtors and debtors-in-possession in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), were prepared in accordance with section 521 of title 11 of the United States Code (the “Bankruptcy Code”), Rule 1007 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), and Rule 1007-1 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the District of Delaware (the “Local Rules”) by management of the Debtors, with the assistance of the Debtors’ professional advisors, and are unaudited and subject to potential adjustment.

The Schedules and Statements have been signed by Lawrence R. Perkins, Chief Restructuring Officer of the Debtors. Given the scale of the Debtors’ businesses, Mr. Perkins has not (nor could have) personally verified the accuracy of each such statement and representation, including, for example, statements and representations concerning amounts owed to creditors, classification of such amounts, and their addresses. In addition, Mr. Perkins has not (nor could have) personally verified the completeness of the Schedules and Statements, nor the accuracy of any information contained therein. In reviewing and signing the Schedules and Statements, Mr. Perkins necessarily relied upon various personnel of the Debtors and the Debtors’ professional advisors and their efforts, statements, and representations in connection therewith. Although management has made reasonable efforts to ensure that the Schedules and Statements are accurate and complete based upon information that was available to them at the time of preparation,

¹ The Debtors in these subchapter V cases, along with the last four digits of each Debtor’s federal tax identification number, if applicable, are as follows: Vyera Pharmaceuticals, LLC (1758); Oakrum Pharma, LLC (3999); SevenScore Pharmaceuticals, LLC (2598); Phoenixus AG (1091); Dermelix Biotherapeutics, LLC (4711); and Orpha Labs AG. The Debtors’ headquarters and the mailing address for the Debtors is 600 3rd Avenue, 19th Floor, New York, NY 10016.

subsequent information or discovery thereof may result in material changes to the Schedules and Statements, and inadvertent errors or omissions may exist.

These Global Notes and Statements of Limitations, Methodology, and Disclaimers Regarding the Debtors' Schedules and Statements (the "Global Notes") pertain to, are incorporated by reference in, and comprise an integral part of all of the Schedules and Statements. The Global Notes should be referred to and reviewed in connection with any review of the Schedules and Statements. The Global Notes are in addition to any specific notes contained in the Debtors' Schedules or Statements. Disclosure of information in one Schedule, Statement, exhibit, or continuation sheet, even if incorrectly placed, shall be deemed to be disclosed in the correct Schedule, Statement, exhibit, or continuation sheet.

The Schedules and Statements, and Global Notes should not be relied upon by any persons for information relating to current or future financial conditions, events, or performance of the Debtors.

Global Notes and Overview of Methodology

1. **General Reservation of Rights.** Although the Debtors' management has made every reasonable effort to ensure that the Schedules and Statements are as accurate and complete as possible under the circumstances based on information that was available to them at the time of preparation, subsequent information or discovery may result in material changes to the Schedules and Statements, and inadvertent errors or omissions may have occurred, some of which may be material. Upon the discovery of materially new information or material errors or omissions, the Debtors will endeavor in good faith to update the Schedules and Statements. Further, because the Schedules and Statements contain unaudited information, which remains subject to further review, verification, and potential adjustment, there can be no assurance that the Schedules and Statements are complete. The Debtors reserve all rights to amend the Schedules and Statements from time to time, in any and all respects, as may be necessary or appropriate, including the right to dispute or otherwise assert offsets or defenses to any claim reflected in the Schedules and Statements as to amount, liability, or classification, or to otherwise subsequently designate any claim ("Claim") as "disputed," "contingent," or "unliquidated." Furthermore, nothing contained in the Schedules and Statements shall constitute an admission of any claims or a waiver of the Debtors' rights with respect to these subchapter V cases, including, without limitation, issues involving substantive consolidation, recharacterization, equitable subordination, and/or causes of action arising under the provisions of chapter 5 of the Bankruptcy Code and other relevant non-bankruptcy laws to recover assets or avoid transfers. Any specific reservation of rights contained elsewhere in the Global Notes does not limit in any respect the general reservation of rights contained in this paragraph.
2. **Subchapter V Designation.** Nothing in the Schedules and Statements nor these Global Notes is, or shall be deemed to be, an admission regarding the Debtors' eligibility, designation, or qualification as a "debtor" as defined in section 1182(1) of the Bankruptcy Code, on a collective or individual debtor basis. The Debtors expressly reserve and do not waive, any and all rights, claims, and defenses with respect to all matters arising from or

related to the Debtors' election to proceed as "debtors" under subchapter V of chapter 11 of the Bankruptcy Code.

3. **Description of Case and "As Of" Information Date.** On May 9, 2023 (the "Petition Date"), the Debtors filed voluntary petitions for relief under chapter 11 of the Bankruptcy Code and elected to proceed under subchapter V thereunder in the Bankruptcy Court. The Debtors continue to operate their businesses and manage their assets as debtors-in-possession pursuant to sections 1107(a), 1108, and 1184 of the Bankruptcy Code. No request for the appointment of a trustee or examiner has been made in these subchapter V cases. Unless otherwise stated herein, assets and liabilities are reported as of April 30, 2023.
4. **Basis of Presentation.** The Schedules and Statements purport to reflect the assets and liabilities of the Debtors. The Debtors reserve all rights relating to the legal ownership of assets and liabilities and nothing in the Schedules or Statements shall constitute a waiver or relinquishment of such rights. Information contained in the Schedules and Statements has been derived from the Debtors' books and records. The Schedules and Statements do not purport to represent financial statements prepared in accordance with Generally Accepted Accounting Principles nor are they intended to be fully reconcilable to audited financial statements. Given, among other things, the uncertainty surrounding the collection, ownership, and valuation of certain assets and the amount and nature of certain liabilities, the Debtors may report more assets than liabilities. Such report shall not constitute an admission that the Debtors were solvent on the Petition Date or at any time prior to or after the Petition Date. Likewise, the Debtors reporting more liabilities than assets shall not constitute an admission that the Debtors were insolvent on the Petition Date or at any time prior to or after the Petition Date.
5. **Totals.** All totals that are included in the Schedules and Statements represent totals of all known amounts included in the Debtors' books and records. To the extent there are unknown or undetermined amounts, the actual totals may be different than the listed total, and the difference may be material. In addition, the amounts shown for total liabilities exclude items identified as "unknown," "disputed," "contingent," "unliquidated," or "undetermined," and, thus, ultimate liabilities may differ materially from those stated in the Schedules and Statements.
6. **Intercompany Receivables and Payables.** Receivables and payables among the Debtors and among the Debtors and their non-Debtor affiliate are reported on Schedule A/B and Schedule E/F, respectively, per the Debtors' books and records. Intercompany loan amounts scheduled may include accrued and unpaid interest. The listing of any amounts with respect to such receivables and payables is not, and should not be construed as, an admission or conclusion of the Debtors' regarding the allowance, classification, validity, or priority of such account or characterization of such balances as debt, equity, or otherwise. For the avoidance of doubt, the Debtors reserve all rights, claims, and defenses in connection with any and all intercompany receivables and payables, including with respect to the characterization of intercompany claims, loans, and notes.

7. **Excluded Assets and Liabilities.** The Debtors have excluded certain categories of assets and liabilities from the Schedules and Statements, including, but not limited to, certain deferred expenses and deferred revenue items, lease assets and related lease liabilities, and certain accrued liabilities. The Debtors have also excluded potential claims arising on account of the potential rejection of executory contracts and unexpired leases, to the extent such claims exist. Certain immaterial assets and liabilities that are not reported or tracked centrally may have been excluded.
8. **Amendments and Supplements; All Rights Reserved.** Reasonable efforts have been made to prepare and file complete and accurate Schedules and Statements; inadvertent errors or omissions, however, may exist. The Debtors reserve all rights, but are not required, to amend and/or supplement the Schedules and Statements from time to time as is necessary and appropriate.
9. **References.** References to applicable loan agreements and related documents are necessary for a complete description of the collateral and the nature, extent, and priority of liens and/or claims. Nothing in the Global Notes or the Schedules and Statements shall be deemed a modification or interpretation of the terms of such agreements.
10. **Currency.** All amounts are reflected in U.S. dollars. Amounts originally denominated in foreign currencies have been converted to US dollar equivalents in accordance with the Debtors' pre-filing accounting practices.
11. **Book Value.** Unless otherwise indicated, the Debtors' assets and liabilities are shown on the basis of its net book values as of April 30, 2023. Thus, unless otherwise noted, the Schedules and Statements reflect the carrying value of the assets and liabilities as recorded on the Debtors' books. Net book values may vary, sometimes materially, from market values. The Debtors do not intend to amend the Schedules and Statements to reflect market values.
12. **Paid Claims.** The Bankruptcy Court authorized the Debtors to pay certain outstanding prepetition Claims—including, but not limited to, payments to employees—pursuant to various “first day” orders entered by the Bankruptcy Court. Accordingly, certain outstanding liabilities as of the Petition Date may have been reduced by postpetition payments made on account of prepetition liabilities. Where the Schedules list creditors and set forth the Debtors' scheduled amount of such Claims, such scheduled amounts reflect amounts owed as of the Petition Date, after incorporating invoices received postpetition for prepetition services. Where the Debtors made postpetition payments on certain prepetition claims pursuant to “first day” orders entered by the Bankruptcy Court, the Schedules may mark such claims as contingent and unliquidated. In addition, to the extent the Debtors later pay any of the Claims listed in the Schedules and Statements pursuant to any orders entered by the Bankruptcy Court, the Debtors reserve all rights to amend or supplement the Schedules and Statements or take other action, such as filing Claim objections, as is necessary and appropriate to avoid overpayment or duplicate payments for liabilities.

13. **Recharacterization.** Notwithstanding that the Debtors have made reasonable efforts to correctly characterize, classify, categorize, or designate certain Claims, assets, executory contracts, unexpired leases, and other items reported in the Schedules and Statements, the Debtors nonetheless may have improperly characterized, classified, categorized, or designated certain items. The Debtors reserve all rights to recharacterize, reclassify, recategorize, or re-designate items reported in the Schedules and Statements at a later time as they determine to be necessary and appropriate prior to any plan or disclosure statement being filed.
14. **Claims of Third-Party Entities.** Although the Debtors have made reasonable efforts to classify properly each Claim listed in the Schedules as being either disputed or undisputed, liquidated or unliquidated, and/or contingent or non-contingent, the Debtors have not been able to fully reconcile all payments made to certain third-party entities on account of the Debtors' obligations to both such entity and its affiliates. Therefore, to the extent that the Debtors have classified its estimate of Claims of a creditor as disputed, for example, all Claims of such creditor's affiliates listed in the Schedules and Statements shall similarly be considered disputed, whether or not they are individually designated as such.
15. **Liabilities.** The Debtors allocate liabilities between the prepetition and postpetition periods based on the information and research conducted in connection with the preparation of the Schedules and Statements. As additional information becomes available, and further research is conducted, particularly with respect to the Debtors' payable accounts, the allocation of liabilities between the prepetition and postpetition periods may change. The Debtors reserve the right to, but is not required to, amend the Schedules and Statements as they deem appropriate to reflect this.
- The liabilities listed on the Schedules and Statements do not reflect any analysis of claims under section 503(b)(9) of the Bankruptcy Code. Accordingly, the Debtors reserve all rights to dispute or challenge the validity of any asserted claims under section 503(b)(9) of the Bankruptcy Code or the characterization of the structure of any such transaction or any document or instrument related to any creditor's Claim.
16. **Guarantees and Other Secondary Liability Claims.** Where guarantees have been identified, they have been included in the relevant liability Schedule for the Debtor affected by such guarantee. The Debtors have also listed guarantees on the applicable Schedule H. It is possible that certain guarantees embedded in the Debtor's executory contracts, unexpired leases, secured financings, debt instruments, and other such agreements may have been inadvertently omitted. The Debtors reserve their right to amend the Schedules to the extent that additional guarantees are identified, or such guarantees are discovered to have expired or be unenforceable.
17. **Intellectual Property Rights.** Exclusion of certain intellectual property shall not be construed to be an admission that such intellectual property rights have been abandoned, have been terminated, or otherwise expired by their terms, or have been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. Conversely, inclusion of certain intellectual property shall not be construed to be an admission that such

intellectual property rights have not been abandoned, have not been terminated, or otherwise expired by their terms, or have not been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. The Debtors have made significant efforts to attribute intellectual property to the rightful Debtor owner. Accordingly, the Debtors reserve all of their rights with respect to the legal status of any and all such intellectual property rights.

18. **Executory Contracts and Unexpired Leases.** The Debtors have not set forth executory contracts or unexpired leases as assets in the Schedules and Statements. The Debtors' executory contracts and unexpired leases have been set forth in Schedule G. In addition, while the Debtors have made diligent attempts to properly identify all executory contracts and unexpired leases, inadvertent errors, omissions, or over-inclusion may have occurred.
19. **Claims Description.** Schedules D and E/F permit the Debtors to designate a Claim as "disputed," "contingent," and/or "unliquidated." Any failure to designate a Claim on a given Debtors' Schedules and Statements as "disputed," "contingent," or "unliquidated" does not constitute an admission by the Debtors that such amounts are not "disputed," "contingent," or "unliquidated" or that such Claims are not subject to objection. The Debtors reserve all rights to dispute any Claim reflected on its Schedules and Statements on any grounds, including, without limitation, liability or classification, or to otherwise subsequently designate such Claims as "disputed," "contingent," or "unliquidated." In addition, the Debtors reserve their rights to object to any listed Claim on the grounds that, among other things, the Claim has already been satisfied.
20. **Causes of Action.** The Debtors are in process of evaluating their individual or collective causes of action or potential causes of action against third parties. Accordingly, the Debtors have not listed specific causes of action or potential causes of action against third parties as assets in its Schedules and Statements, including, without limitation, avoidance actions arising under chapter 5 of the Bankruptcy Code and actions under other relevant non-bankruptcy laws to recover assets. The Debtors reserve all of their rights for any claims, causes of action, or avoidance actions they may have, and neither these Global Notes nor the Schedules and Statements shall be deemed a waiver of any such claims, causes of actions, or avoidance actions or in any way prejudice or impair the assertion of such claims.

The Debtors will reserve all rights to include any causes of action or potential causes of action against third parties in any amended version of the Debtors' *Joint Subchapter V Plan of Reorganization and Liquidation* [D.I. 11] (the "Plan") or any supplement or addendum thereto.

21. **Undetermined Amounts.** Claim amounts that could not readily be quantified by the Debtors are scheduled as "unknown," "TBD," or "undetermined". The description of an amount as "unknown," "TBD," or "undetermined" is not intended to reflect upon the materiality of such amount.
22. **Liens.** Property and equipment listed in the Schedules and Statements are presented without consideration of any liens that may attach (or have attached) to such property or equipment.

23. **Estimates.** To prepare and file the Schedules as close to the Petition Date as possible and within the time frame dictated by Local Rule 1007-1(b), management was required to make certain estimates and assumptions that affected the reported amounts of these assets and liabilities. The Debtors reserve all rights to amend the reported amounts of assets and liability to reflect changes in those estimates or assumptions.
24. **Credits and Adjustments.** The claims of individual creditors for, among other things, goods, products, services, or taxes are listed as the amounts entered on the Debtors' books and records and may not reflect credits, allowances, or other adjustments due from such creditors to the Debtors. The Debtors reserve all of their rights with regard to such credits, allowances, and other adjustments, including, without limitation, the right to assert claims objections and/or setoffs with respect to the same.
25. **Setoffs.** The Debtors incur certain setoffs and other similar rights during the ordinary course of business. Offsets in the ordinary course can result from various items, including, without limitation, intercompany transactions, pricing discrepancies, returns, warranties, negotiations, and/or disputes between the Debtors and its vendors and customers. These offsets and other similar rights are consistent with the ordinary course of business in the Debtors' industry and are not tracked separately. Therefore, although such offsets and other similar rights may have been accounted for when certain amounts were included in the Schedules, offsets are not independently accounted for, and as such, are excluded from the Schedules.
26. **Global Notes Control.** In the event that the Schedules and Statements differ from these Global Notes, the Global Notes shall control.

General Disclosures Applicable to Schedules

27. **Classifications.** Listing a Claim (a) on Schedule D as "secured," (b) on Schedule E/F as "priority," or (c) on Schedule E/F as "unsecured," or a contract on Schedule G as "executory" or "unexpired," does not in each case constitute an admission by the Debtors of the legal rights of the claimant, or a waiver of the Debtors' right to recharacterize or reclassify such Claim or contract.
28. **Schedule A/B - Real and Personal Property.**
 - a) Schedule A/B.3. Bank account balances are as of the end of business on Petition Date.
 - b) Schedule A/B.15. For purposes of these Schedules, the value of the Debtors' interests is undetermined. The book values of certain assets may materially differ from their fair market values and/or the liquidation of the assets prepared in connection with the proposed Plan.
29. **Schedule E/F— Creditors Holding Unsecured Claims.** The Debtors have not listed on Schedule E/F any tax related obligations. The Debtors believe that any such Claims have

been or will be satisfied in the ordinary course during these subchapter V cases pursuant to the authority granted in the relevant order.

The Debtors have used reasonable efforts to report all general unsecured Claims against the Debtors on Schedule E/F based upon the Debtors' existing books and records as of the Petition Date; however, inadvertent errors or omissions may have occurred. The Claims listed on Schedule E/F arose or were incurred on various dates. In certain instances, the date on which a Claim arose is an open issue of fact. In addition, the Claims of individual creditors for, among other things, goods or services are listed as either the lower of the amounts invoiced by such creditor or the amounts entered on the Debtors' books and records and may not reflect credits, rebates, or allowances due from such creditors to the Debtors. The Claims and amounts listed in respect of certain trade payables reflect amounts owed as of the Petition Date.

The Debtors may pay additional Claims listed on Schedule E/F during these subchapter V cases pursuant orders of the Bankruptcy Court and reserves all of its rights to update Schedule E/F to reflect such payments, as applicable. In addition, certain Claims listed on Schedule E/F may be entitled to priority under section 503(b)(9) of the Bankruptcy Code.

Schedule E/F also reports employee claims arising in the ordinary course of business related to wages, salaries, and other employee benefits, including paid time off. Pursuant to the *Interim Order Authorizing the Debtors to Maintain and Continue Payment of Employee Compensation and Employee Benefit Programs (II) Authorizing and Directing Banks to Honor and Process Checks and Transfers Related to Such Employee Obligations and (III) Granting Related Relief* [D.I. 50] (the "Interim Wage Order"),² amounts earned within 180 days of the Petition Date and under the cap set by section 507(a)(4) of the Bankruptcy Code will be paid in the ordinary course of business, subject to exceptions as set forth in the Interim Wage Order. As such, certain prepetition amounts for wages have already been paid and are excluded from being presented in the Schedules. For the sake of clarity, to the extent the Debtors later pay any of the Claims listed in the Schedules and Statements pursuant to any orders entered by the Bankruptcy Court, the Debtors reserve all rights to amend or supplement the Schedules and Statements or take other action, such as filing Claim objections, as is necessary and appropriate to avoid overpayment or duplicate payments for liabilities.

30. **Schedule G — Executory Contracts and Unexpired Leases.** While reasonable efforts have been made to ensure the accuracy of Schedule G, the Debtors' businesses are complex, and inadvertent errors, omissions, or overinclusion may have occurred. Each lease and contract listed in Schedule G may include one or more ancillary documents, including any underlying assignment and assumption agreements, amendments, supplements, full and partial assignments, renewals and partial releases, which may not be listed on Schedule G. Certain of the leases and contracts listed on Schedule G may contain certain renewal options, guarantees of payment, options to purchase, rights of first refusal, and other

² The relief granted in the Interim Wage Order is subject to final approval by the Bankruptcy Court. As of the filing of the Schedules and Statements, a hearing is set for June 14, 2023 before the Bankruptcy Court to consider such final approval.

miscellaneous rights. Such rights, powers, duties, and obligations are not set forth on Schedule G. In addition, the Debtors may have entered into various other types of agreements in the ordinary course of business, indemnity agreements, subordination, non-disturbance agreements, supplemental agreements, amendments/letter agreements, title agreements, and confidentiality agreements. Such documents may not be set forth on Schedule G. Certain of the executory contracts may not have been memorialized in writing and could be subject to dispute.

The Debtors reserve all of their rights to dispute the validity, status, or enforceability of any contracts, agreements, or leases set forth in Schedule G and to amend or supplement such Schedule as necessary. Omission of a contract or agreement from Schedule G does not constitute an admission that such omitted contract or agreement is not an executory contract or unexpired lease. Likewise, inclusion of any agreement on Schedule G does not constitute an admission that such agreement is an executory contract or unexpired lease, or that such agreement was in effect on the Petition Date or is valid and enforceable, and the Debtors reserve all rights in that regard, including, that any agreement is not executory, has expired pursuant to its terms, or was terminated prepetition.

31. **Schedule H — Co-debtors.** Although the Debtors have made every effort to ensure the accuracy of Schedule H, inadvertent errors, omissions, or inclusions may have occurred. The Debtors hereby reserve all rights to dispute the validity, status, and enforceability of any obligations set forth on Schedule H and to further amend or supplement such Schedule as necessary.

The Debtors further reserve all rights, claims, and causes of action with respect to the obligations listed on Schedule H, including the right to dispute or challenge the characterization or the structure of any transaction, document, or instrument related to a creditor's claim. The listing of a contract, guarantee, or other obligation on Schedule H shall not be deemed an admission that such obligation is binding, valid, or enforceable.

In the ordinary course of its business, the Debtors are involved in pending or threatened litigation and claims arising out of the conduct of its business. These matters may involve multiple plaintiffs and defendants, some or all of whom may assert cross-claims and counterclaims against other parties. Because such claims are listed elsewhere in the Statements and Schedules, they may not have been set forth individually on Schedule H.

Schedule H also may reflect guarantees by the Debtors. The Debtors may not have identified certain guarantees that are embedded in the Debtors' executory contracts, unexpired leases, debt instruments, and other such agreements. Further, the Debtors believe that certain of the guarantees reflected on Schedule H may have expired or may no longer be enforceable. Thus, the Debtors reserve their right, but shall not be required, to amend the Schedules to the extent that additional guarantees are identified, or such guarantees are discovered to have expired or are unenforceable.

General Disclosures Applicable to Statements

32. **Question 3.** For certain creditors receiving payment, the Debtors maintains multiple addresses for such vendor. Efforts have been made to attribute the correct address, however, in certain instances, alternate addresses may be applicable for a party listed in response to Question 3.
33. **Question 4.** For purposes of the Schedules and Statements, the Debtors defines insiders as individuals that, based upon the totality of circumstances, have a controlling interest in, or exercise sufficient control over the Debtors so as to dictate corporate policy and the disposition of assets. The Debtors do not take any position with respect to (a) such person's influence over the control of the Debtors; (b) the management responsibilities or functions of such individual; (c) the decision-making or corporate authority of such individual; or (d) whether such individual could successfully argue that he or she is not an "insider" under applicable law, including the federal securities law, or with respect to any theories of liability or any other purpose. As such, the Debtors reserves all rights to dispute whether someone identified in response to Question 4 is in fact an "insider" as defined in section 101(31) of the Bankruptcy Code.
34. **Question 7.** The Debtors reserve all of their rights and defenses with respect to any and all listed lawsuits and administrative proceedings. The listing of any such suits and proceedings shall not constitute an admission by the Debtors of any liabilities or that the actions or proceedings were correctly filed against the Debtors. The Debtors also reserve their rights to assert that a Debtor is not an appropriate party to such actions or proceedings.
35. **Question 10.** The Debtors have made best efforts to collect applicable and responsive information, however, certain *de minimis* losses, which are not tracked separately, may have been omitted.
36. **Question 13.** While the Debtors have made reasonable efforts to respond comprehensively to Question 13, certain *de minimis* asset sales and transfers may be omitted unintentionally.
37. **Question 26d.** The Debtors routinely provide financial information to current and potential banks, customers, suppliers, advisors, governmental authorities, landlords, investors, and other financial institutions in the ordinary course.
38. **Question 30.** For this question, please reference Statement of Financial Affairs, Question 4.

Fill in this information to identify the case:

Debtor	Phoenixus AG
United States Bankruptcy Court for the:	Delaware
Case number (if known)	23-10606

Check if this is an amended filing

Official Form 206Sum

Summary of Assets and Liabilities for Non-Individuals

12/15

Part 1: Summary of Assets

1. **Schedule A/B: Assets-Real and Personal Property** (Official Form 206A/B)

1a. **Real property:**

Copy line 88 from *Schedule A/B*

UNKNOWN

1b. **Total personal property:**

Copy line 91A from *Schedule A/B*

\$72,784,221.54

1c. **Total of all property:**

Copy line 92 from *Schedule A/B*

\$72,784,221.54

Part 2: Summary of Liabilities

2. **Schedule D: Creditors Who Have Claims Secured by Property** (Official Form 206D)

Copy the total dollar amount listed in Column A, *Amount of claim*, from line 3 of *Schedule D*

NOT APPLICABLE

3. **Schedule E/F: Creditors Who Have Unsecured Claims** (Official Form 206EF)

3a. **Total claim amounts of priority unsecured claims:**

Copy the total claims from Part 1 from line 5a of *Schedule E/F*

NOT APPLICABLE

3b. **Total amount of claims of nonpriority amount of unsecured claims:**

Copy the total of the amount of claims from Part 2 from line 5b of *Schedule E/F*

+	\$9,053,752.54
---	----------------

4. **Total liabilities**

Lines 2 + 3a + 3b

\$9,053,752.54

Fill in this information to identify the case:

Debtor Phoenixus AG

United States Bankruptcy Court for the: Delaware

Case number (if known) 23-10606

Check if this is an amended filing

Official Form 206A/B

Schedule A/B: Assets - Real and Personal Property

12/15

Disclose all property, real and personal, which the debtor owns or in which the debtor has any other legal, equitable, or future interest. Include all property in which the debtor holds rights and powers exercisable for the debtor's own benefit. Also include assets and properties which have no book value, such as fully depreciated assets or assets that were not capitalized. In Schedule A/B, list any executory contracts or unexpired leases. Also list them on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G).

Be as complete and accurate as possible. If more space is needed, attach a separate sheet to this form. At the top of any pages added, write the debtor's name and case number (if known). Also identify the form and line number to which the additional information applies. If an additional sheet is attached, include the amounts from the attachment in the total for the pertinent part.

For Part 1 through Part 11, list each asset under the appropriate category or attach separate supporting schedules, such as a fixed asset schedule or depreciation schedule, that gives the details for each asset in a particular category. List each asset only once. In valuing the debtor's interest, do not deduct the value of secured claims. See the instructions to understand the terms used in this form.

Part 1: CASH AND CASH EQUIVALENTS

1. DOES THE DEBTOR HAVE ANY CASH OR CASH EQUIVALENTS?

- No. Go to Part 2.
- Yes. Fill in the information below.

All cash or cash equivalents owned or controlled by the debtor

Current value of debtor's interest

2. CASH ON HAND

NONE

3. CHECKING, SAVINGS, MONEY MARKET, OR FINANCIAL BROKERAGE ACCOUNTS (IDENTIFY ALL)

Name of institution (bank or brokerage firm)	Type of account	Last 4 digits of account number	
3.1. CREDIT SUISSE	BROKERAGE	4251	\$0.00
3.2. CREDIT SUISSE	OPERATING	9421	\$364,742.12
3.3. CREDIT SUISSE	OPERATING	9422	\$733,718.22
3.4. POSTFINANCE AG	OPERATING	9177	\$30,037.65

4. OTHER CASH EQUIVALENTS

NONE

5 Total of Part 1.
ADD LINES 2 THROUGH 4 (INCLUDING AMOUNTS ON ANY ADDITIONAL SHEETS). COPY THE TOTAL TO LINE 80.

\$1,128,497.99

Part 2: DEPOSITS AND PREPAYMENTS

6. DOES THE DEBTOR HAVE ANY DEPOSITS OR PREPAYMENTS?

- No. Go to Part 3.
- Yes. Fill in the information below.

Current value of debtor's interest

(Name)

Current value of debtor's interest

7. DEPOSITS, INCLUDING SECURITY DEPOSITS AND UTILITY DEPOSITS

DESCRIPTION, INCLUDING NAME OF HOLDER OF DEPOSIT

7.1. RENT DEPOSIT - FISCOM \$15,000.00

8. PREPAYMENTS, INCLUDING PREPAYMENTS ON EXECUTORY CONTRACTS, LEASES, INSURANCE, TAXES, AND RENT

DESCRIPTION, INCLUDING NAME OF HOLDER OF PREPAYMENT

8.1. A&M SECURITIES LLC PROFESSIONAL FEE RETAINER \$225,000.00

8.2. DLA PIPER LLP PROFESSIONAL FEE RETAINER \$1,517,672.00

8.3. PREPAID INSURANCE - MARSH USA INC. \$1,708,010.69

8.4. SIERRACONSTELLATION PARTNERS LLC PROFESSIONAL FEE RETAINER \$698,841.89

9 Total of Part 2.

ADD LINES 7 THROUGH 8. COPY THE TOTAL TO LINE 81.

\$4,164,524.58

Part 3: ACCOUNTS RECEIVABLE

10. DOES THE DEBTOR HAVE ANY ACCOUNTS RECEIVABLE?

- No. Go to Part 4.
- Yes. Fill in the information below.

Current value of debtor's interest

11. ACCOUNTS RECEIVABLE

12 Total of Part 3.

CURRENT VALUE ON LINES 11A + 11B = LINE 12. COPY THE TOTAL TO LINE 82.

NOT APPLICABLE

Part 4: INVESTMENTS

13. DOES THE DEBTOR OWN ANY INVESTMENTS?

- No. Go to Part 5.
- Yes. Fill in the information below.

Valuation method used for current value

Current value of debtor's interest

14. MUTUAL FUNDS OR PUBLICLY TRADED STOCKS NOT INCLUDED IN PART 1

NAME OF FUND OR STOCK:

14.1. REGNUM CORP N/A UNKNOWN

15. NON-PUBLICLY TRADED STOCK AND INTERESTS IN INCORPORATED AND UNINCORPORATED BUSINESSES, INCLUDING ANY INTEREST IN AN LLC, PARTNERSHIP, OR JOINT VENTURE

Name of entity	% of ownership	Valuation method used for current value	Current value of debtor's interest
15.1. DERMELIX BIOTHERAPUEUTICS, LLC	100%	N/A	UNKNOWN
15.2. OAKRUM PHARMA, LLC	100%	N/A	UNKNOWN
15.3. ORPHA LABS AG	100%	N/A	UNKNOWN
15.4. SEVENSORE PHARMACEUTICALS LLC	100%	N/A	UNKNOWN
15.5. VYERA PHARMACEUTICALS, LLC	100%	N/A	UNKNOWN

16. GOVERNMENT BONDS, CORPORATE BONDS, AND OTHER NEGOTIABLE AND NON-NEGOTIABLE INSTRUMENTS NOT INCLUDED IN PART 1

DESCRIBE:

(Name)

Valuation method used for current value Current value of debtor's interest

17 Total of Part 4.
ADD LINES 14 THROUGH 16. COPY THE TOTAL TO LINE 83.

UNKNOWN

Part 5: INVENTORY, EXCLUDING AGRICULTURE ASSETS

18. DOES THE DEBTOR OWN ANY INVENTORY (EXCLUDING AGRICULTURE ASSETS)?

- No. Go to Part 6.
- Yes. Fill in the information below.

General description	Date of the last physical inventory	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
19. RAW MATERIALS				
NONE				
20. WORK IN PROGRESS				
NONE				
21. FINISHED GOODS, INCLUDING GOODS HELD FOR RESALE				
21.1. DARAPRIM PILLS	N/A	\$58,248.00	NBV	\$58,248.00

22. OTHER INVENTORY OR SUPPLIES
NONE

23 Total of Part 5.
ADD LINES 19 THROUGH 22. COPY THE TOTAL TO LINE 84.

\$58,248.00

24. Is any of the property listed in Part 5 perishable?

- No
- Yes

25. Has any of the property listed in Part 5 been purchased within 20 days before the bankruptcy was filed?

- No
- Yes Book value _____ Valuation method _____ Current value _____

26. Has any of the property listed in Part 5 been appraised by a professional within the last year?

- No
- Yes

Part 6: FARMING AND FISHING-RELATED ASSETS (OTHER THAN TITLED MOTOR VEHICLES AND LAND)

27. DOES THE DEBTOR OWN OR LEASE ANY FARMING AND FISHING-RELATED ASSETS (OTHER THAN TITLED MOTOR VEHICLES AND LAND)?

- No. Go to Part 7.
- Yes. Fill in the information below.

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
28. CROPS—EITHER PLANTED OR HARVESTED			
29. FARM ANIMALS EXAMPLES: LIVESTOCK, POULTRY, FARM-RAISED FISH EXAMPLES: LIVESTOCK, POULTRY, FARM-RAISED FISH			
30. FARM MACHINERY AND EQUIPMENT (OTHER THAN TITLED MOTOR VEHICLES) (OTHER THAN TITLED MOTOR VEHICLES)			
31. FARM AND FISHING SUPPLIES, CHEMICALS, AND FEED			

(Name)

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
32. OTHER FARMING AND FISHING-RELATED PROPERTY NOT ALREADY LISTED IN PART 6			
33 Total of Part 6. ADD LINES 28 THROUGH 32. COPY THE TOTAL TO LINE 85.			NOT APPLICABLE
34. Is the debtor a member of an agricultural cooperative? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Is any of the debtor's property stored at the cooperative? <input type="checkbox"/> No <input type="checkbox"/> Yes			
35. Has any of the property listed in Part 6 been purchased within 20 days before the bankruptcy was filed? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes			
36. Is a depreciation schedule available for any of the property listed in Part 6? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes			
37. Has any of the property listed in Part 6 been appraised by a professional within the last year? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes			

Part 7: OFFICE FURNITURE, FIXTURES, AND EQUIPMENT; AND COLLECTIBLES

38. DOES THE DEBTOR OWN OR LEASE ANY OFFICE FURNITURE, FIXTURES, EQUIPMENT, OR COLLECTIBLES? <input type="checkbox"/> No. Go to Part 8. <input checked="" type="checkbox"/> Yes. Fill in the information below.			
General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
39. OFFICE FURNITURE			
39.1. VARIOUS OFFICE DESKS, CHAIRS, CONFERENCE TABLE AND CHAIRS	UNKNOWN	N/A	UNKNOWN
40. OFFICE FIXTURES			
41. OFFICE EQUIPMENT, INCLUDING ALL COMPUTER EQUIPMENT AND COMMUNICATION SYSTEMS EQUIPMENT AND SOFTWARE			
41.1. VARIOUS COMPUTERS, LAPTOPS, MONITORS, SERVERS	UNKNOWN	N/A	UNKNOWN
42. COLLECTIBLES EXAMPLES: ANTIQUES AND FIGURINES; PAINTINGS, PRINTS, OR OTHER ARTWORK; BOOKS, PICTURES, OR OTHER ART OBJECTS; CHINA AND CRYSTAL; STAMP, COIN, OR BASEBALL CARD COLLECTIONS; OTHER COLLECTIONS, MEMORABILIA, OR COLLECTIBLES <i>EXAMPLES: ANTIQUES AND FIGURINES; PAINTINGS, PRINTS, OR OTHER ARTWORK; BOOKS, PICTURES, OR OTHER ART OBJECTS; CHINA AND CRYSTAL; STAMP, COIN, OR BASEBALL CARD COLLECTIONS; OTHER COLLECTIONS, MEMORABILIA, OR COLLECTIBLES</i>			
43 Total of Part 7. ADD LINES 39 THROUGH 42. COPY THE TOTAL TO LINE 86.			UNKNOWN
44. Is a depreciation schedule available for any of the property listed in Part 7? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes			
45. Has any of the property listed in Part 7 been appraised by a professional within the last year? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes			

(Name)

Part 8: MACHINERY, EQUIPMENT, AND VEHICLES

46. DOES THE DEBTOR OWN OR LEASE ANY MACHINERY, EQUIPMENT, OR VEHICLES?

- No. Go to Part 9.
- Yes. Fill in the information below.

General description Include year, make, model, and identification numbers (i.e., VIN, HIN, or N-number)	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
--	--	---	------------------------------------

47. AUTOMOBILES, VANS, TRUCKS, MOTORCYCLES, TRAILERS, AND TITLED FARM VEHICLES

48. WATERCRAFT, TRAILERS, MOTORS, AND RELATED ACCESSORIES EXAMPLES: BOATS, TRAILERS, MOTORS, FLOATING HOMES, PERSONAL WATERCRAFT, AND FISHING VESSELS

49. AIRCRAFT AND ACCESSORIES

50. OTHER MACHINERY, FIXTURES, AND EQUIPMENT (EXCLUDING FARM MACHINERY AND EQUIPMENT)

51. Total of Part 8.
ADD LINES 47 THROUGH 50. COPY THE TOTAL TO LINE 87.

NOT APPLICABLE

52. Is a depreciation schedule available for any of the property listed in Part 8?

- No
- Yes

53. Has any of the property listed in Part 8 been appraised by a professional within the last year?

- No
- Yes

Part 9: REAL PROPERTY

54. DOES THE DEBTOR OWN OR LEASE ANY REAL PROPERTY?

- No. Go to Part 10.
- Yes. Fill in the information below.

55. ANY BUILDING, OTHER IMPROVED REAL ESTATE, OR LAND WHICH THE DEBTOR OWNS OR IN WHICH THE DEBTOR HAS AN INTEREST

Description and location of property Include street address or other description such as Assessor Parcel Number (APN), and type of property (for example, acreage, factory, warehouse, apartment or office building), if available	Nature and extent of debtor's interest in property	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
---	--	--	---	------------------------------------

55.1. HALDENSTRASSE 5, 6340 BAAR SWITZERLAND	OFFICE LEASE	UNKNOWN	N/A	UNKNOWN
--	--------------	---------	-----	---------

56. Total of Part 9.
ADD THE CURRENT VALUE ON LINES 55.1 THROUGH 55.6 AND ENTRIES FROM ANY ADDITIONAL SHEETS. COPY THE TOTAL TO LINE 88.

UNKNOWN

57. Is a depreciation schedule available for any of the property listed in Part 9?

- No
- Yes

58. Has any of the property listed in Part 9 been appraised by a professional within the last year?

- No
- Yes

Part 10: INTANGIBLES AND INTELLECTUAL PROPERTY**59. DOES THE DEBTOR HAVE ANY INTERESTS IN INTANGIBLES OR INTELLECTUAL PROPERTY?**

- No. Go to Part 11.
- Yes. Fill in the information below.

General description		Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
60. PATENTS, COPYRIGHTS, TRADEMARKS, AND TRADE SECRETS				
60.1.	OAKRUM - SWITZERLAND APPLICATION NO. 110702019	UNKNOWN	N/A	UNKNOWN
60.2.	OAKRUM - U.S. APPLICATION NO. 88626593	UNKNOWN	N/A	UNKNOWN
60.3.	OAKRUM PHARMA - SWITZERLAND APPLICATION NO. 110712019	UNKNOWN	N/A	UNKNOWN
60.4.	OAKRUM PHARMA - U.S. APPLICATION NO. 88626607	UNKNOWN	N/A	UNKNOWN
60.5.	TURING - AUSTRALIA APPLICATION NO. 1736978	UNKNOWN	N/A	UNKNOWN
60.6.	TURING - BRAZIL APPLICATION NO. 910322066	UNKNOWN	N/A	UNKNOWN
60.7.	TURING - CHINA APPLICATION NO. 18461297	UNKNOWN	N/A	UNKNOWN
60.8.	TURING - EUROPEAN UNION APPLICATION NO. 14835219	UNKNOWN	N/A	UNKNOWN
60.9.	TURING - HONG KONG APPLICATION NO. 303610520	UNKNOWN	N/A	UNKNOWN
60.10.	TURING - JAPAN APPLICATION NO. 2015116253	UNKNOWN	N/A	UNKNOWN
60.11.	TURING - MEXICO APPLICATION NO. 1685650	UNKNOWN	N/A	UNKNOWN
60.12.	TURING - NEW ZEALAND APPLICATION NO. 1032469	UNKNOWN	N/A	UNKNOWN
60.13.	TURING - REPUBLIC OF KOREA APPLICATION NO. 4020150088476	UNKNOWN	N/A	UNKNOWN
60.14.	TURING - RUSSIAN FEDERATION APPLICATION NO. 2015738640	UNKNOWN	N/A	UNKNOWN
60.15.	TURING - SINGAPORE APPLICATION NO. 40201520795U	UNKNOWN	N/A	UNKNOWN
60.16.	TURING - SWITZERLAND APPLICATION NO. 648652015	UNKNOWN	N/A	UNKNOWN
60.17.	TURING - TAIWAN APPLICATION NO. 104070370	UNKNOWN	N/A	UNKNOWN
60.18.	TURING - U.S. APPLICATION NO. 86644505	UNKNOWN	N/A	UNKNOWN
60.19.	TURING - UNITED KINGDOM APPLICATION NO. 14835219	UNKNOWN	N/A	UNKNOWN
60.20.	TURING PHARMACEUTICALS - AUSTRALIA APPLICATION NO. 1736979	UNKNOWN	N/A	UNKNOWN
60.21.	TURING PHARMACEUTICALS - BRAZIL APPLICATION NO. 910322139	UNKNOWN	N/A	UNKNOWN
60.22.	TURING PHARMACEUTICALS - CHINA APPLICATION NO. 18461298	UNKNOWN	N/A	UNKNOWN
60.23.	TURING PHARMACEUTICALS - EUROPEAN UNION APPLICATION NO. 14835243	UNKNOWN	N/A	UNKNOWN
60.24.	TURING PHARMACEUTICALS - HONG KONG APPLICATION NO. 303610539	UNKNOWN	N/A	UNKNOWN
60.25.	TURING PHARMACEUTICALS - JAPAN APPLICATION NO. 2015116254	UNKNOWN	N/A	UNKNOWN
60.26.	TURING PHARMACEUTICALS - MEXICO APPLICATION NO. 1685651	UNKNOWN	N/A	UNKNOWN
60.27.	TURING PHARMACEUTICALS - NEW ZEALAND APPLICATION NO. 1032470	UNKNOWN	N/A	UNKNOWN
60.28.	TURING PHARMACEUTICALS - REPUBLIC OF KOREA APPLICATION NO. 4020150088469	UNKNOWN	N/A	UNKNOWN
60.29.	TURING PHARMACEUTICALS - RUSSIAN FEDERATION APPLICATION NO. 2015738645	UNKNOWN	N/A	UNKNOWN

(Name)

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
60. PATENTS, COPYRIGHTS, TRADEMARKS, AND TRADE SECRETS			
60.30. TURING PHARMACEUTICALS - SINGAPORE APPLICATION NO. 40201520805S	UNKNOWN	N/A	UNKNOWN
60.31. TURING PHARMACEUTICALS - SWITZERLAND APPLICATION NO. 648672015	UNKNOWN	N/A	UNKNOWN
60.32. TURING PHARMACEUTICALS - TAIWAN APPLICATION NO. 104070371	UNKNOWN	N/A	UNKNOWN
60.33. TURING PHARMACEUTICALS - U.S. APPLICATION NO. 86644527	UNKNOWN	N/A	UNKNOWN
60.34. TURING PHARMACEUTICALS - UNITED KINGDOM APPLICATION NO. 14835243	UNKNOWN	N/A	UNKNOWN
60.35. VECAMYL - CANADA APPLICATION NO. 1666757	UNKNOWN	N/A	UNKNOWN
60.36. VECAMYL - U.S. APPLICATION NO. 85278488	UNKNOWN	N/A	UNKNOWN
60.37. VYERA - AUSTRALIA APPLICATION NO. 1872964	UNKNOWN	N/A	UNKNOWN
60.38. VYERA - CHINA APPLICATION NO. 1364919	UNKNOWN	N/A	UNKNOWN
60.39. VYERA - EUROPEAN UNION REG. NO. 1364919	UNKNOWN	N/A	UNKNOWN
60.40. VYERA - HONG KONG APPLICATION NO. 304208724	UNKNOWN	N/A	UNKNOWN
60.41. VYERA - INDIA APPLICATION NO. 3640606	UNKNOWN	N/A	UNKNOWN
60.42. VYERA - INTERNATIONAL BUREAU (WIPO) APPLICATION NO. A0068475	UNKNOWN	N/A	UNKNOWN
60.43. VYERA - JAPAN APPLICATION NO. 1364919	UNKNOWN	N/A	UNKNOWN
60.44. VYERA - MEXICO APPLICATION NO. 1947528	UNKNOWN	N/A	UNKNOWN
60.45. VYERA - NEW ZEALAND APPLICATION NO. 1076064	UNKNOWN	N/A	UNKNOWN
60.46. VYERA - REPUBLIC OF KOREA	UNKNOWN	N/A	UNKNOWN
60.47. VYERA - RUSSIAN FEDERATION APPLICATION NO. 1364919	UNKNOWN	N/A	UNKNOWN
60.48. VYERA - SINGAPORE APPLICATION NO. 40201718027S	UNKNOWN	N/A	UNKNOWN
60.49. VYERA - SWITZERLAND REG. NO. 1364919	UNKNOWN	N/A	UNKNOWN
60.50. VYERA - TAIWAN APPLICATION NO. 106043831	UNKNOWN	N/A	UNKNOWN
60.51. VYERA - U.S. APPLICATION NO. 87304375	UNKNOWN	N/A	UNKNOWN
60.52. VYERA - UNITED KINGDOM APPLICATION NO. 1364919	UNKNOWN	N/A	UNKNOWN
60.53. VYERA PHARMACEUTICALS - AUSTRALIA APPLICATION NO. 1945665	UNKNOWN	N/A	UNKNOWN
60.54. VYERA PHARMACEUTICALS - CHINA APPLICATION NO. 1415622	UNKNOWN	N/A	UNKNOWN
60.55. VYERA PHARMACEUTICALS - EUROPEAN UNION APPLICATION NO. 1415622	UNKNOWN	N/A	UNKNOWN
60.56. VYERA PHARMACEUTICALS - HONG KONG APPLICATION NO. 304505742	UNKNOWN	N/A	UNKNOWN
60.57. VYERA PHARMACEUTICALS - INDIA APPLICATION NO. 3908317	UNKNOWN	N/A	UNKNOWN
60.58. VYERA PHARMACEUTICALS - INTERNATIONAL BUREAU (WIPO) APPLICATION NO. A0075400	UNKNOWN	N/A	UNKNOWN
60.59. VYERA PHARMACEUTICALS - JAPAN APPLICATION NO. 1415622	UNKNOWN	N/A	UNKNOWN
60.60. VYERA PHARMACEUTICALS - NEW ZEALAND APPLICATION NO. 1099242	UNKNOWN	N/A	UNKNOWN
60.61. VYERA PHARMACEUTICALS - RUSSIAN FEDERATION APPLICATION NO. 1415622	UNKNOWN	N/A	UNKNOWN

(Name)

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
60. PATENTS, COPYRIGHTS, TRADEMARKS, AND TRADE SECRETS			
60.62. VYERA PHARMACEUTICALS - SINGAPORE APPLICATION NO. 40201815439V	UNKNOWN	N/A	UNKNOWN
60.63. VYERA PHARMACEUTICALS - SWITZERLAND APPLICATION NO. 1415622	UNKNOWN	N/A	UNKNOWN
60.64. VYERA PHARMACEUTICALS - TAIWAN APPLICATION NO. 107027397	UNKNOWN	N/A	UNKNOWN
60.65. VYERA PHARMACEUTICALS - U.S. APPLICATION NO. 87673086	UNKNOWN	N/A	UNKNOWN
60.66. VYERA PHARMACEUTICALS - UNITED KINGDOM APPLICATION NO. 1415622	UNKNOWN	N/A	UNKNOWN
60.67. VYERA THERAPEUTICS - HONG KONG APPLICATION NO. 304208733	UNKNOWN	N/A	UNKNOWN
60.68. VYERA THERAPEUTICS - TAIWAN APPLICATION NO. 106043832	UNKNOWN	N/A	UNKNOWN
61. INTERNET DOMAIN NAMES AND WEBSITES			
61.1. WWW.ORPHAN-STAR.COM	UNKNOWN	N/A	UNKNOWN
61.2. WWW.PHOENIXUS.COM	UNKNOWN	N/A	UNKNOWN
61.3. WWW.PHOENIXUSAG.COM	UNKNOWN	N/A	UNKNOWN
61.4. WWW.PHOENIXUSHOLDINGS.INFO	UNKNOWN	N/A	UNKNOWN
62. LICENSES, FRANCHISES, AND ROYALTIES			
63. CUSTOMER LISTS, MAILING LISTS, OR OTHER COMPILATIONS			
64. OTHER INTANGIBLES, OR INTELLECTUAL PROPERTY			
65. GOODWILL			
66 Total of Part 10. ADD LINES 60 THROUGH 65. COPY THE TOTAL TO LINE 89.			UNKNOWN
67. Do your lists or records include personally identifiable information of customers (as defined in 11 U.S.C. §§ 101(41A) and 107)? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes			
68. Is there an amortization or other similar schedule available for any of the property listed in Part 10? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes			
69. Has any of the property listed in Part 10 been appraised by a professional within the last year? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes			
Part 11: ALL OTHER ASSETS			
70. DOES THE DEBTOR OWN ANY OTHER ASSETS THAT HAVE NOT YET BEEN REPORTED ON THIS FORM? INCLUDE ALL INTERESTS IN EXECUTORY CONTRACTS AND UNEXPIRED LEASES NOT PREVIOUSLY REPORTED ON THIS FORM. <input type="checkbox"/> No. Go to Part 12. <input checked="" type="checkbox"/> Yes. Fill in the information below.			
			Current value of debtor's interest
71. NOTES RECEIVABLE DESCRIPTION (INCLUDE NAME OF OBLIGOR) NONE			

(Name)

Current value of
debtor's interest**72. TAX REFUNDS AND UNUSED NET OPERATING LOSSES (NOLS)**

DESCRIPTION (FOR EXAMPLE, FEDERAL, STATE, LOCAL)

72.1.	FEDERAL NOL (SWITZERLAND)	Tax year	2020	\$8,794,639.00
72.2.	FEDERAL NOL (SWITZERLAND)	Tax year	2021	\$19,721,003.00
72.3.	FEDERAL NOL (SWITZERLAND)	Tax year	2022	\$9,335,617.00

73. INTERESTS IN INSURANCE POLICIES OR ANNUITIES

73.1.	AFB / HISCOX POLICY FINMW2250348	UNKNOWN
73.2.	AIG EUROPE S.A. POLICY FINMW2250349	UNKNOWN
73.3.	AIG EUROPE SA - D&O POLICY FINMW2350405	UNKNOWN
73.4.	ARGONAUGHT INSURANCE COMPANY POLICY ML4262536-1	UNKNOWN
73.5.	COALITION POLICY C-4LXD-064237-CYBER-2021	UNKNOWN
73.6.	DUAL / STARTPOINT POLICY FINMW2250351	UNKNOWN
73.7.	DUAL CORPORATE RISKS LIMITED - D&O POLICY FINMW2350407	UNKNOWN
73.8.	INDIAN HARBOR INSURANCE COMPANY POLICY ELU182090-22	UNKNOWN
73.9.	INGIO POLICY FINMW2250346	UNKNOWN
73.10.	IRONSHORE SPECIALTY INSURANCE COMPANY POLICY HC7SACBB98002	UNKNOWN
73.11.	LLOYD'S SYNDICATE HIS 0033 - D&O POLICY FINMW2350884	UNKNOWN
73.12.	LLOYD'S SYNDICATE IGO 1301 - D&O POLICY FINMW2350403	UNKNOWN
73.13.	LLOYD'S SYNDICATE IGO 1301 - D&O POLICY FINMW2350403	UNKNOWN
73.14.	LLOYDS OF LONDON POLICY BOWCI22250863	UNKNOWN
73.15.	WRB + ALPHA DUA POLICY FINMW2250347	UNKNOWN

74. CAUSES OF ACTION AGAINST THIRD PARTIES (WHETHER OR NOT A LAWSUIT HAS BEEN FILED)

74.1. SEE GLOBAL NOTES

Nature of claim

Amount requested

75. OTHER CONTINGENT AND UNLIQUIDATED CLAIMS OR CAUSES OF ACTION OF EVERY NATURE, INCLUDING COUNTERCLAIMS OF THE DEBTOR AND RIGHTS TO SET OFF CLAIMS

75.1. SEE GLOBAL NOTES

Nature of claim

Amount requested

76. TRUSTS, EQUITABLE OR FUTURE INTERESTS IN PROPERTY

NONE

77. OTHER PROPERTY OF ANY KIND NOT ALREADY LISTED EXAMPLES: SEASON TICKETS, COUNTRY CLUB MEMBERSHIP EXAMPLES: SEASON TICKETS, COUNTRY CLUB MEMBERSHIP

77.1.	INTERCOMPANY RECEIVABLE FROM DERMELIX BIOTHERAPUETICS LLC	\$3,422,482.85
77.2.	INTERCOMPANY RECEIVABLE FROM OAKRUM PHARMA, LLC	\$13,723,938.18
77.3.	INTERCOMPANY RECEIVABLE FROM ORPHA LABS AG	\$7,285,029.01
77.4.	INTERCOMPANY RECEIVABLE FROM REGNUM CORP	\$1,566,615.45
77.5.	INTERCOMPANY RECEIVABLE FROM SEVENSORE PHARMACUETICALS, LLC	\$3,583,626.48

(Name)

78 Total of Part 11.
 ADD LINES 71 THROUGH 77. COPY THE TOTAL TO LINE 90. \$67,432,950.97

79. Has any of the property listed in Part 11 been appraised by a professional within the last year?
 No
 Yes

Part 12: Summary

In Part 12 copy all of the totals from the earlier parts of the form.

	Current value of personal property	Current value of real property
80. Cash, cash equivalents, and financial assets. <i>Copy line 5, Part 1.</i>	\$1,128,497.99	
81. Deposits and prepayments. <i>Copy line 9, Part 2.</i>	\$4,164,524.58	
82. Accounts receivable. <i>Copy line 12, Part 3.</i>		
83. Investments. <i>Copy line 17, Part 4.</i>	UNKNOWN	
84. Inventory. <i>Copy line 23, Part 5.</i>	\$58,248.00	
85. Farming and fishing-related assets. <i>Copy line 33, Part 6.</i>		
86. Office furniture, fixtures, and equipment; and collectibles. <i>Copy line 43, Part 7.</i>	UNKNOWN	
87. Machinery, equipment, and vehicles. <i>Copy line 51, Part 8.</i>		
88. Real property. <i>Copy line 56, Part 9.</i> →		UNKNOWN
89. Intangibles and intellectual property. <i>Copy line 66, Part 10.</i>	UNKNOWN	
90. All other assets. <i>Copy line 78, Part 11.</i>	+	\$67,432,950.97
91. Total. Add lines 80 through 90 for each column. 91a.	\$72,784,221.54	+ 91b. UNKNOWN
92. Total of all property on Schedule A/B. Lines 91a + 91b = 92.		\$72,784,221.54

Fill in this information to identify the case:

Debtor	<u>Phoenixus AG</u>
United States Bankruptcy Court for the:	<u>Delaware</u>
Case number (if known)	<u>23-10606</u>

Check if this is an amended filing

Official Form 206D

Schedule D: Creditors Who Have Claims Secured by Property

12/15

Be as complete and accurate as possible.

1. **1. Do any creditors have claims secured by debtor's property?**
 - No. Check this box and submit page 1 of this form to the court with debtor's other schedules. Debtor has nothing else to report on this form.
 - Yes. Fill in all of the information below.

Fill in this information to identify the case:

Debtor Phoenixus AG

United States Bankruptcy Court for the: Delaware

Case number 23-10606
(if known)

Check if this is an amended filing

Official Form 206E/F

Schedule E/F: Creditors Who Have Unsecured Claims

12/15

Be as complete and accurate as possible. Use Part 1 for creditors with PRIORITY unsecured claims and Part 2 for creditors with NONPRIORITY unsecured claims. List the other party to any executory contracts or unexpired leases that could result in a claim. Also list executory contracts on *Schedule A/B: Assets - Real and Personal Property* (Official Form 206A/B) and on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G). Number the entries in Parts 1 and 2 in the boxes on the left. If more space is needed for Part 1 or Part 2, fill out and attach the Additional Page of that Part included in this form.

Part 1: List All Creditors with PRIORITY Unsecured Claims

1. Do any creditors have priority unsecured claims? (See 11 U.S.C. § 507).
- No. Go to Part 2.
- Yes. Go to line 2.

Part 2: List All Creditors with NONPRIORITY Unsecured Claims

- Do any creditors have nonpriority unsecured claims? (See 11 U.S.C. § 507).
- No.
- Yes.

3. List in alphabetical order all of the creditors with nonpriority unsecured claims. If the debtor has more than 6 creditors with nonpriority unsecured claims, fill out and attach the Additional Page of Part 2.

Amount of claim

		Amount of claim
3.1	<p>Nonpriority creditor's name and mailing address</p> <p>AUSGLEICHSKASSE ZUG BAARERSTRASSE 11 ZUG 6304 SWITZERLAND</p> <p>Date or dates debt was incurred</p> <p>Last 4 digits of account number:</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: TAXES</p> <p>Is the claim subject to offset?</p> <p><input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>
3.2	<p>Nonpriority creditor's name and mailing address</p> <p>CEROVENE, INC. 12 CORPORATE WAY, SUITE 10 VALLEY COTTAGE, NY 10989</p> <p>Date or dates debt was incurred</p> <p>Last 4 digits of account number:</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input checked="" type="checkbox"/> Contingent <input checked="" type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed</p> <p>Basis for the claim: LITIGATION</p> <p>Is the claim subject to offset?</p> <p><input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>

(Name)

Part 2: Additional Page

			Amount of claim
3.3	<p>Nonpriority creditor's name and mailing address DR. REDDY'S LABORATORIES, INC. 107 COLLEGE RD E PRINCETON, NJ 08540</p> <p>Date or dates debt was incurred</p> <p>Last 4 digits of account number:</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input checked="" type="checkbox"/> Contingent <input checked="" type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed</p> <p>Basis for the claim: LITIGATION</p> <p>Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>	UNKNOWN
3.4	<p>Nonpriority creditor's name and mailing address DUANE MORRIS 30 S. 17TH STREET PHILADELPHIA, PA 19103</p> <p>Date or dates debt was incurred</p> <p>Last 4 digits of account number:</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed</p> <p>Basis for the claim: PROFESSIONAL SERVICES</p> <p>Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>	\$2,127,923.43
3.5	<p>Nonpriority creditor's name and mailing address EFORM SOLUTIONS AG HALDENSTRASSE 5 BAAR 6340 SWITZERLAND</p> <p>Date or dates debt was incurred</p> <p>Last 4 digits of account number:</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: TRADE PAYABLE</p> <p>Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>	\$3,931.06
3.6	<p>Nonpriority creditor's name and mailing address FEDERAL TRADE COMMISSION AND VARIOUS STATE AG'S 1 BOWLING GREEN #318 NEW YORK, NY 10004</p> <p>Date or dates debt was incurred</p> <p>Last 4 digits of account number:</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: SETTLEMENT AGREEMENT</p> <p>Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>	\$0.00
3.7	<p>Nonpriority creditor's name and mailing address KANT. STEUERVERWALTUNG BAHNHOFSTRASSE 26 ZUG 6300 SWITZERLAND</p> <p>Date or dates debt was incurred</p> <p>Last 4 digits of account number:</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: TAXES</p> <p>Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>	\$14,226.65

(Name)

Part 2: Additional Page

			Amount of claim
3.8	Nonpriority creditor's name and mailing address LGM PHARMA SOLUTIONS, LLC 6400 CONGRESS AVE SUITE 1400 BOCA RATON, FL 33487 Date or dates debt was incurred Last 4 digits of account number:	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: TRADE PAYABLE Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$33,000.00
3.9	Nonpriority creditor's name and mailing address STADTANTENNEN AG BACHWEID 20 BAAR 6340 SWITZERLAND Date or dates debt was incurred Last 4 digits of account number:	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: TRADE PAYABLE Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$940.00
3.10	Nonpriority creditor's name and mailing address VYERA PHARMACUETICALS, LLC 660 THIRD AVE 19TH FLOOR NEW YORK, NY 10016 Date or dates debt was incurred VARIOUS Last 4 digits of account number:	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: INTERCOMPANY Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$6,860,962.75

Part 4: Total Amounts of the Priority and Nonpriority Unsecured Claims

5. Add the amounts of priority and nonpriority unsecured claims.

		Total of claim amounts
5a.	Total claims from Part 1	5a. <u>NOT APPLICABLE</u>
5b.	Total claims from Part 2	5b. + <u>\$9,053,752.54</u>
5c.	Total of Parts 1 and 2 Lines 5a + 5b = 5c.	5c. <u>\$9,053,752.54</u>

Fill in this information to identify the case:

Debtor Phoenixus AG

United States Bankruptcy Court for the: Delaware

Case number 23-10606
(if known)

Check if this is an amended filing

Official Form 206G

Schedule G: Executory Contracts and Unexpired Leases

12/15

Be as complete and accurate as possible. If more space is needed, copy and attach the additional page, numbering the entries consecutively.

1. Does the debtor have any executory contracts or unexpired leases?
- No. Check this box and file this form with the court with the debtor's other schedules. There is nothing else to report on this form.
- Yes. Fill in all of the information below even if the contracts or leases are listed on *Schedule A/B: Assets - Real and Personal Property* (Official Form 206A/B).

2. List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.1	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>		<p>ACUTALIS THERAPUETICS AG C/O GEORGE CARIBALI HIRZBODENPARK 18 BASEL 4052 SWITZERLAND</p>
2.2	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>		<p>AESICA PHARMACUETICALS LIMITED SUITE B, BREAKSPEAR PARK BREAKSPEAR WAY HEMEL HEMPSTEAD HERTFORDSHIRE ENGLAND</p>
2.3	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>CONVERTIBLE LOAN AGREEMENT</p> <p>State the term remaining</p> <p>TERMINATED</p> <p>List the contract number of any government contract</p>		<p>ALAN GELLAR ADDRESS ON FILE</p>
2.4	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>MANDATE AGREEMENT</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>		<p>ALEXANDRE ZYNGIER ADDRESS ON FILE</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.5	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ENGAGEMENT LETTER</p>	<p>ALVAREZ & MARSAL SECURITIES, LLC 600 MADISON AVE 8TH FLOOR NEW YORK, NY 10022</p>
2.6	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>FIRST AND SECOND AMENDMENT TO THE DATA LICENSE AGREEMENT</p> <p>UNKNOWN</p>	<p>AMEDRA PHARMACEUTICALS LLC AND WALGREEN CO. 2 WALNUT GROVE DRIVE AUIITE 190 HORSHAM, PA 19044</p>
2.7	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ASSIGNMENT AND ASSUMPTION AGREEMENT</p>	<p>AMEDRA PHARMACEUTICALS LLC 2 WALNUT GROVE DRIVE AUIITE 190 HORSHAM, PA 19044</p>
2.8	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>AMENDMENT TO THE TRANSFER AGENCY AND REGISTRAR SERVICES AGREEMENT</p> <p>AUTO RENEW</p>	<p>AMERICAN STOCK TRANSFER & TRUST COMPANY LLC PO BOX 12893 PHILADELPHIA, PA 19176-0893</p>
2.9	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>TRANSFER AGENCY AND REGISTRAR SERVICES AGREEMENT DATED 2/26/2019</p>	<p>AMERICAN STOCK TRANSFER & TRUST COMPANY LLC PO BOX 12893 PHILADELPHIA, PA 19176-0893</p>
2.10	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>LOAN AGREEMENT</p>	<p>ANTHION PARTNERS II LLC 379 WEST BORADWAY SUITE 311 NEW YORK, NY 10012</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.11	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>MAY 2024</p>	<p>ARISO PHARMA GMBH WALLENRODER STRASSE 8-10 BERLIN 13435 GERMANY</p>
2.12	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>HR SUPPORT, CONSULTING AND RECRUITMENT AGREEMENT</p> <p>UNKNOWN</p>	<p>AURIGAVISION AG BAARERSTASSE 139 ZUG CH 6300 SWITZERLAND</p>
2.13	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>OCTOBER 2023</p>	<p>AURIS MEDICAL HOLDING LTD CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM11 BERMUDA</p>
2.14	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>EMPLOYMENT AGREEMENT</p>	<p>AVERILL POWERS ADDRESS ON FILE</p>
2.15	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANDATE AGREEMENT</p> <p>TERMINATED</p>	<p>AVERILL POWERS ADDRESS ON FILE</p>
2.16	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>NOVEMBER 2020</p>	<p>BIOSYNTH AG RIETLISTRASSE 4 STAAD 9422 SWITZERLAND</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.17	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ENGAGEMENT LETTER</p>	<p>BRAG BUNDESSTRASSE 3 POSTFACH ZUG CH-6302 SWITZERLAND</p>
2.18	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>LOAN AGREEMENT</p> <p>TERMINATED</p>	<p>CADUCEUS PHARMACEUTICALS, LLC 4361 N STATE ROAD 7 FORT LAUDERDALE, FL 33319-4856</p>
2.19	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ENGAGEMENT LETTER</p> <p>TERMINATED</p>	<p>CHARDAN CAPITAL MARKERS 17 STATE STREET SUITE 1600 NEW YORK, NY 10004</p>
2.20	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ENGAGEMENT LETTER</p>	<p>CHOATE, HALL & STEWART LLP TWO INTERNATIONAL PALACE ATTN: MICHAEL GASS BOSTON, MA 02110-4104</p>
2.21	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p>	<p>CORDENPHARMA INTERNATIONAL GMBH OTTO-HAHN STRASSE PLANKSTADT 68723 GERMANY</p>
2.22	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ASSIGNMENT AND ASSUMPTION AGREEMENT</p>	<p>COREPHARMA, LLC 215 WOOD AVE MIDDLESEX, NJ 08846</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.23	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANUFACTURING KNOW-HOW SUBLICENSE AGREEMENT</p> <p>PERPETUAL</p>	<p>COREPHARMA, LLC 215 WOOD AVE MIDDLESEX, NJ 08846</p>
2.24	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>TRADEMARK SUBLICENSE AGREEMENT</p> <p>PERPETUAL</p>	<p>COREPHARMA, LLC 215 WOOD AVE MIDDLESEX, NJ 08846</p>
2.25	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>JUNE 2020</p>	<p>CU CHEMIE UETIKON GMBH RAIFFEISENSTRASSE 4 LAHR 77933 GERMANY</p>
2.26	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANDATE AGREEMENT</p> <p>PERPETUAL</p>	<p>DEREK PITTS ADDRESS ON FILE</p>
2.27	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ENGAGEMENT LETTER</p>	<p>DLA PIPER LLP 444 WEST LAKE STREET SUITE 900 CHICAGO, IL 60606</p>
2.28	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>LOAN AGREEMENT</p> <p>TERMINATED</p>	<p>DOS MINEIROS CAPITAL FUND 4TH FLOOR, HARBOUR PLACE 103 SOUTH STREET PO BOX 10240 GRAND CAYMAN KY1-1002 CAYMAN ISLANDS</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.29	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANDATE AGREEMENT</p> <p>JUNE 2023</p>	<p>DR JENS SCHLEGEL ADDRESS ON FILE</p>
2.30	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANDATE AGREEMENT</p> <p>DECEMBER 2025</p>	<p>DR PHIL HAROUN FRICK ADDRESS ON FILE</p>
2.31	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MASTER CONSULTANT AGREEMENT</p> <p>MARCH 2017</p>	<p>DR PHIL HAROUN FRICK ADDRESS ON FILE</p>
2.32	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>STATEMENT OF WORK NO.1 AND AMENDMENT</p> <p>UNKNOWN</p>	<p>DR PHIL HAROUN FRICK ADDRESS ON FILE</p>
2.33	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p>	<p>DR. THOMAS P. KOESTLER ADDRESS ON FILE</p>
2.34	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>MARCH 2023</p>	<p>EDWIN J THOMAS ADDRESS ON FILE</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.35	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	IT SUPPORT AND MAINTENANCE CONTRACT	EFORMS SOLUTIONS ADDRESS ON FILE
2.36	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT NOVEMBER 2023	FAREVA SA 28 PLACE DE LA GARE LUXEMBOURG 1616 LUXEMBOURG
2.37	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	LEASE UNKNOWN	FISCOM CONSULTING GMBH HALDENSTRASSE 5 / PF 1359 BAAR 1359 SWITZERLAND
2.38	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	MASTER SERVICES AGREEMENT AUTO RENEW	FUKUZYU PHARMACEUTICALS COMPANY LTD. 48 HAGIWARA TOYAMA 939-8261 JAPAN
2.39	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	QUALITY AGREEMENT	FUKUZYU PHARMACEUTICALS COMPANY LTD. 48 HAGIWARA TOYAMA 939-8261 JAPAN
2.40	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	MANDATE AGREEMENT PERPETUAL	GERALD YARDY ADDRESS ON FILE

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.41	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>CONVERTIBLE LOAN AGREEMENT</p> <p>TERMINATED</p>	<p>GREGORY REA ADDRESS ON FILE</p>
2.42	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p>	<p>HELSINN ADVANCED SYNTHESIS SA VIA INDUSTRIA 24 BIASCA 6710 SWITZERLAND</p>
2.43	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ASSIGNMENT AND ASSUMPTION AGREEMENT</p>	<p>IMPAX LABORATORIES, INC. 31047 GENSTAR ROAD HAYWARD, CA 94544</p>
2.44	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>PURCHASE AGREEMENT DATED 8/7/15</p>	<p>IMPAX LABORATORIES, INC. 31047 GENSTAR ROAD HAYWARD, CA 94544</p>
2.45	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>APRIL 2022</p>	<p>INNOMAR STRATEGIES INC. 3470 SUPERIOR COURT OAKVILLE, ON L6L 0C4 CANADA</p>
2.46	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>AMENDMENT AND ASSIGNMENT AND ASSUMPTION AGREEMENT</p> <p>UNKNOWN</p>	<p>INTEGRATED COMMERCIALIZATION SOLUTIONS, LLC 195 EAST ELK TRAIL CAROL STREAM, IL 60188</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.47	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>SUPPLY CHAIN SERVICES AGREEMENT</p> <p>AUTO RENEW</p>	<p>INTEGRATED COMMERCIALIZATION SOLUTIONS, LLC 195 EAST ELK TRAIL CAROL STREAM, IL 60188</p>
2.48	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANDATE AGREEMENT</p> <p>PERPETUAL</p>	<p>IVONA SMITH ADDRESS ON FILE</p>
2.49	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>CONVERTIBLE LOAN AGREEMENT</p> <p>TERMINATED</p>	<p>KEVIN MULLEADY ADDRESS ON FILE</p>
2.50	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>QUALITY AGREEMENT</p> <p>UNKNOWN</p>	<p>LGM PHARMA 17802 GILLETE AVE IRVINE, CA 92614</p>
2.51	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>LEASE</p> <p>TERMINATED</p>	<p>LIENHARDT & PARTNER PRIVATBANK ZURISH AG ZURICH 8024 SWITZERLAND</p>
2.52	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>OCTOBER 2022</p>	<p>LINCOLN INTERNATIONAL LLC 110 NORTH WACKER DRIVE 51ST FLOOR CHICAGO, IL 60606</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.53	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>MARCH 2023</p>	<p>MIGUEL BARRON ADDRESS ON FILE</p>
2.54	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANDATE AGREEMENT</p> <p>TERMINATED</p>	<p>MIGUEL BARRON ADDRESS ON FILE</p>
2.55	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>AMENDMENT NO. 1 TO THE RESTATED LICENSE AND MANUFACTURING AGREEMENT</p> <p>UNKNOWN</p>	<p>NEXGEN PHARMA INC. 46 CORPORATE PARK SUITE 100 IRVINE, CA 92606</p>
2.56	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>JANUARY 2020</p>	<p>NEXGEN PHARMA INC. 46 CORPORATE PARK SUITE 100 IRVINE, CA 92606</p>
2.57	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>RESTATED LICENSE AND MANUFACTURING AGREEMENT</p>	<p>NEXGEN PHARMA INC. 46 CORPORATE PARK SUITE 100 IRVINE, CA 92606</p>
2.58	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>QUALITY AGREEMENT</p>	<p>NOVITIUM PHARMA LLC 70 LAKE DRIVE EAST WINDSOR, NJ 08520</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.59	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT</p> <p>SEPTEMBER 2024</p>	<p>NOVITIUM PHARMA LLC 70 LAKE DRIVE EAST WINDSOR, NJ 08520</p>
2.60	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>QUALITY AGREEMENT</p>	<p>OAKRUM PHARMA LLC 3636 GEYER ROAD SUITE 100 ST. LOUIS, MO 63127</p>
2.61	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>SALES AND DISTRIBUTION AGREEMENT</p> <p>MAY 2026</p>	<p>OAKRUM PHARMA LLC 3636 GEYER ROAD SUITE 100 ST. LOUIS, MO 63127</p>
2.62	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MASTER MANUFACTURING SERVICES AGREEMENT</p> <p>TERMINATED</p>	<p>PATHEON MANUFACTURING SERVICES, LLC 5900 MARTIN LUTHER KING JR. HIGHWAY GREENVILLE, NC 27834</p>
2.63	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>PRODUCT AGREEMENT</p> <p>TERMINATED</p>	<p>PATHEON MANUFACTURING SERVICES, LLC 5900 MARTIN LUTHER KING JR. HIGHWAY GREENVILLE, NC 27834</p>
2.64	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>QUALITY AGREEMENT</p> <p>TERMINATED</p>	<p>PATHEON MANUFACTURING SERVICES, LLC 5900 MARTIN LUTHER KING JR. HIGHWAY GREENVILLE, NC 27834</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.65	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>DEVELOPMENT AND SUPPLY AGREEMENT</p> <p>PERPETUAL</p>	<p>PIRAMAL ENTERPRISES LTD. PIRAMAL ANANTA AGASTYA CORPORATE PARK KAMANI JUNCTION, LBS MARG MUMBAI INDIA</p>
2.66	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>QUALITY AGREEMENT</p>	<p>PIRAMAL ENTERPRISES LTD. PIRAMAL ANANTA AGASTYA CORPORATE PARK KAMANI JUNCTION, LBS MARG MUMBAI INDIA</p>
2.67	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>COMMISSION AGREEMENT</p>	<p>PMC PHARMA MANAGEMENT CONSULTANTS GMBH ALISBACHWEG 22 C OBERAEGERI 6315 SWITZERLAND</p>
2.68	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>FEBRUARY 2023</p>	<p>PMC PHARMA MANAGEMENT CONSULTANTS GMBH ALISBACHWEG 22 C OBERAEGERI 6315 SWITZERLAND</p>
2.69	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>FEBRUARY 2022</p>	<p>PORTAGE POINT PARTNERS LLC 300 NORTH LASALLE SUITE 1420 CHICAGO, IL 60654</p>
2.70	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p>	<p>RAYMOND JAMES FINANCIAL, INC. 880 CARILLON PARKWAY ST. PETERSBURG, FL 33716</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.71	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	ASSET PURCHASE AGREEMENT DATED 1/9/2015	RETROPHIN, INC. 777 THIRD AVE 22ND FLOOR NEW YORK, NY 10017
2.72	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	ASSET PURCHASE AGREEMENT DATED 2/12/2015	RETROPHIN, INC. 777 THIRD AVE 22ND FLOOR NEW YORK, NY 10017
2.73	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	ASSET PURCHASE AGREEMENT DATED 2/12/2015	RETROPHIN, INC. 777 THIRD AVE 22ND FLOOR NEW YORK, NY 10017
2.74	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	ASSET PURCHASE AGREEMENT DATED 2/17/2015	RETROPHIN, INC. 777 THIRD AVE 22ND FLOOR NEW YORK, NY 10017
2.75	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	PURCHASE AGREEMENT DATED 2/12/2015	RETROPHIN, INC. 777 THIRD AVE 22ND FLOOR NEW YORK, NY 10017
2.76	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	DISTRIBUTION AND SUPPLY AGREEMENT TERMINATED	RL FINE CHEM PVT. LTD. RLFC HOUSE C-10 1ST CORSS KSSIDC, INDUSTRIAL ESTATE YELAHANKA BENGALURU 560064 INDIA

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.77	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>RESTRICTED STOCK UNIT AWARD AGREEMENT PURSUANT TO 2015 OMNIBUS INCENTIVE PLAN</p>	<p>RON TILES ADDRESS ON FILE</p>
2.78	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p>	<p>ROTTENDORF PHARMA INC. 3805 VALLEY COMMONS DRIVE SUITE 9 BOZEMAN, MT 59718</p>
2.79	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>JULY 2024</p>	<p>SAI LIFE SCIENCES LTD. CORPORATE OFFICE #L4-06 SLN TERMINUS SURVEY NO. 133 GACHIBOWLI MUYAPUR ROAD, GACHIBOWLI HYDERABAD 500032 INDIA</p>
2.80	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ASSET PURCHASE AGREEMENT</p>	<p>SEELOS THERAPEUTICS, INC. 209 LUKES WOOD ROAD NEW CANAAN, CT 06840</p>
2.81	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>TRANSITION SERVICES AGREEMENT</p>	<p>SEELOS THERAPEUTICS, INC. 209 LUKES WOOD ROAD NEW CANAAN, CT 06840</p>
2.82	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>HUMAN CAPITAL MANAGEMENT AND STRATEGY CONSULTING AGREEMENT</p> <p>PERPETUAL</p>	<p>SFR SEARCH 1 NEVEADA PLAZA NEW YORK, NY 10023</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.83	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ENGAGEMENT LETTER</p> <p>JANUARY 2021</p>	<p>SIERRACONSTELLATION PARTNERS 355 SOTUH GRAND AVE SUITE 1450 LOS ANGELES, CA 90071</p>
2.84	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>JANUARY 2021</p>	<p>SIGMA ALDRICH CHEMIE GMBH INDUSTRIESTRASSE 25 BUCHS 9470 SWITZERLAND</p>
2.85	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>QUALITY AGREEMENT</p> <p>MARCH 2020</p>	<p>SMITH MEDICAL PARTNERS, LLC 195 EAST ELK TRAIL CAROL STREAM, IL 60188</p>
2.86	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>SUPPLY CHAIN SERVICES AGREEMENT</p> <p>MARCH 2020</p>	<p>SMITH MEDICAL PARTNERS, LLC 195 EAST ELK TRAIL CAROL STREAM, IL 60188</p>
2.87	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>NOVEMBER 2023</p>	<p>SPIROCHEM AG ROSENTAL AREA WRO-1047-3 MATTENSTRASSES 24 BASEL 4058 SWITZERLAND</p>
2.88	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MASTER SERVICES AGREEMENT AND AMENDMENTS</p>	<p>STA PHARMACUETICAL HONG KONG LIMITED FLAT/ROOM 1303 13F BEVERLY HOUSE 93-107 LOCKHART ROAD, WANCHAI HONG KONG CHINA</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.89	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>OCTOBER 2023</p>	<p>STEROP NV AVENUE DE SCHEUT 46-50 BRUSSELS 1070 BELGIUM</p>
2.90	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>EXCLUSIVE LICENSE AGREEMENT</p> <p>PERPETUAL</p>	<p>STUART WEG, MD ADDRESS ON FILE</p>
2.91	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>DECEMBER 2020</p>	<p>SYNLAB ANALYTICS & SERVICES GERMANY GMBH GUBENER STRASSES 39 AUGSBURG 85156 GERMANY</p>
2.92	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANDATE AGREEMENT</p> <p>PERPETUAL</p>	<p>THOMAS J. ALLISON ADDRESS ON FILE</p>
2.93	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>OCTOBER 2024</p>	<p>TORREYA CAPITAL LLC 555 MADISON AVE SUITE 1201 NEW YORK, NY 10022</p>
2.94	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT</p> <p>AUGUST 2022</p>	<p>TRACON PHARMACEUTICALS INC 4350 LA JOLLA VILLAGE DRIVE SUITE 800 SAN DIEGO, CA 92122</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.95	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>SALES AND DISTRIBUTION AGREEMENT</p> <p>JANUARY 2025</p>	<p>TURING PHARMACEUTICALS LLC (DISTRIBUTOR) 600 THIRD AVE 19TH FLOOR NEW YORK, NY 10016</p>
2.96	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>SUPPORT SERVICES AGREEMENT</p> <p>UNKNOWN</p>	<p>TURING PHARMACEUTICALS LLC 600 THIRD AVE 19TH FLOOR NEW YORK, NY 10016</p>
2.97	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ENGAGEMENT LETTER</p>	<p>VISCHER AG AESCHENVORSTADT 4 BASEL CH-4010 SWITZERLAND</p>
2.98	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>ASSET PURCHASE AGREEMENT</p>	<p>WALDUN PHARMACEUTICALS LLC C/O BRIAN SMITH 251 LORING AVE PELHAM, NY 10803</p>
2.99	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>DATA LICENSE AGREEMENT</p>	<p>WALGREENS CO. PO BOX 653039 DALLAS, TX 75265-3039</p>
2.100	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>FIRST AND SECOND AMENDMENT TO THE DATA LICENSE AGREEMENT</p>	<p>WALGREENS CO. PO BOX 653039 DALLAS, TX 75265-3039</p>

(Name)

List all contracts and unexpired leases		State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease	
2.101	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>MANDATE AGREEMENT</p> <p>TERMINATED</p>	<p>WALTER BLUM ADDRESS ON FILE</p>
2.102	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>CONFIDENTIALITY AGREEMENT</p> <p>MAY 2023</p>	<p>WAVE CORPORATE FINANCE BV TAALSTRAAT 40 VUGHT 5261 BE NETHERLANDS</p>
2.103	<p>State what the contract or lease is for and the nature of the debtor's interest</p> <p>State the term remaining</p> <p>List the contract number of any government contract</p>	<p>CONVERTIBLE LOAN AGREEMENT</p> <p>TERMINATED</p>	<p>WORMWOOD CAPITAL LLC 1246 NE OCEANVIEW CIRCLE JENSEN BEACH, FL 34957</p>

Fill in this information to identify the case:

Debtor Phoenixus AG

United States Bankruptcy Court for the: Delaware

Case number 23-10606
(if known)

Check if this is an amended filing

Official Form 206H

Schedule H: Codebtors

12/15

Be as complete and accurate as possible. If more space is needed, copy the Additional Page, numbering the entries consecutively. Attach the Additional Page to this page.

1. Does the debtor have any codebtors?

- No. Check this box and submit this form to the court with the debtor's other schedules. Nothing else needs to be reported on this form.
 Yes.

2. In Column 1, list as codebtors all of the people or entities who are also liable for any debts listed by the debtor in the schedules of creditors, Schedules D-G. Include all guarantors and co-obligors. In Column 2, identify the creditor to whom the debt is owed and each schedule on which the creditor is listed. If the codebtor is liable on a debt to more than one creditor, list each creditor separately in Column 2.

Column 1: Codebtor		Column 2: Creditor	
Name	Mailing Address	Name	Check all schedules that apply
2.1 VYERA PHARMACEUTICALS, LLC	600 3RD AVENUE 19TH FLOOR NEW YORK, NY 10016	CEROVENE, INC.	<input type="checkbox"/> D <input checked="" type="checkbox"/> E/F <input type="checkbox"/> G
2.2 VYERA PHARMACEUTICALS, LLC	600 3RD AVENUE 19TH FLOOR NEW YORK, NY 10016	DR. REDDY'S LABORATORIES, INC.	<input type="checkbox"/> D <input checked="" type="checkbox"/> E/F <input type="checkbox"/> G
2.3 VYERA PHARMACEUTICALS, LLC	600 3RD AVENUE 19TH FLOOR NEW YORK, NY 10016	DUANE MORRIS	<input type="checkbox"/> D <input checked="" type="checkbox"/> E/F <input type="checkbox"/> G
2.4 VYERA PHARMACEUTICALS, LLC	600 3RD AVENUE 19TH FLOOR NEW YORK, NY 10016	FEDERAL TRADE COMMISSION AND VARIOUS STATE AG'S	<input type="checkbox"/> D <input checked="" type="checkbox"/> E/F <input type="checkbox"/> G

Debtor	<u>Phoenixus AG</u>
United States Bankruptcy Court for the:	<u>Delaware</u>
Case number (if known)	<u>23-10606</u>

Official Form 202

Declaration Under Penalty of Perjury for Non-Individual Debtors

12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- Schedule A/B: Assets-Real and Personal Property* (Official Form 206A/B)
- Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- Schedule H: Codebtors* (Official Form 206H)
- Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- Amended *Schedule*
- Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders* (Official Form 204)
- Other document that requires a declaration

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 06/02/2023
MM / DD / YYYY

X /s/ Lawrence R. Perkins
Signature of individual signing on behalf of debtor

Lawrence R. Perkins
Printed name

Chief Restructuring Officer
Position or relationship to debtor